Skip to main content
OpenTrials
Completed

NCT Number: NCT02146963

Study of the BDNF-Val66Met Polymorphism in Alcohol-dependent Subjects in Relation to Abstinence After Withdrawal

This study is complementary to the main study "Brain Derived Neurotrophic Factor Serum Levels Evolution During the Six Months After Alcohol Withdrawal " NCT01491347.

The purpose of this study is to evaluate the Bdnf gene - Val66Met polymorphism in subjects with alcohol dependence according to their alcohol consumption status 6 months after withdrawal (relapse or abstinence), in relation to the presence of psychiatric co-morbidities.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Alcohol Dependence Alcohol-Related Disorders Alcoholism Chemically-Induced Disorders Mental Disorders Substance-Related Disorders

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Centre Hospitalier Esquirol

Limoges, 87025, France

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • participation to the study "BDNF serum levels evolution during 6 months after alcohol withdrawal" (main study)
  • criteria from the main study

Exclusion criteria

  • criteria from the main study
  • released or out from the main study before the follow-up at 4 months after withdrawal

Treatment and study plan

Primary outcomes

  1. Frequency of the Bdnf gene Val/Val, Val/Met and Met/Met phenotypes as a function of relapse

    Time frame: at the time of inclusion

Secondary outcomes

  1. serum BDNF levels variations between inclusion and 6 months later (or 4 months if the participants does not come for the 4 months-follow-up).

    Time frame: 6 months after alcohol withdrawal

  2. existence of a psychiatric co-morbidity at the inclusion (major depression, schizophrenia, anxiety disorder)

    Time frame: at the time of inclusion

  3. presence of a psychiatric co-morbidity at 6 months after withdrawal (major depression, schizophrenia, anxiety disorder)

    Time frame: 6 month after alcohol withdrawal

Sponsors and collaborators

Lead sponsor

Centre Hospitalier Esquirol

Other

Collaborators

  • Institut National de la Santé Et de la Recherche Médicale, France

Registry information

Official study title

Study of the BDNF- Val66Met Polymorphism in Alcohol-dependent Subjects in Relation to Abstinence After Withdrawal

Important dates

Study start
2014
Primary completion
2016
Study completion
2016
First posted
May 26, 2014
Registry last updated
Jan 31, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.